| This week's sponsor is CMIC Group. | | | |
Today's Rundown Genentech joins immune tolerance field with Parvus hookup Actuate raises $22M to expand GSK-3β cancer trial Takeda teams up with Frazier Healthcare for GI biotech launch How a parasitic fish inspired a new way to get drugs into the brain EuroBiotech Report—Bayer's $150M site, Merck, F-star, Philogen round and roxa data FiercePharmaAsia—Post-Shire Takeda outlook; generics price-fixing suit; Daiichi’s leukemia woe Chutes & Ladders—AstraZeneca nets executive to lead breast cancer R&D Featured Story | | | Friday, May 17, 2019 Genentech has teamed up with Parvus Therapeutics to develop immune tolerance drugs. The Roche subsidiary put together an $800 million-plus deal to work with Parvus on drugs to treat autoimmune diseases. |
|
|
Top Stories Friday, May 17, 2019 Actuate Therapeutics has raised $21.7 million to take its lead oncology asset deeper into the clinic. The series B round comes shortly after Actuate dosed the first patient in a phase 1/2 trial of glycogen synthase kinase‐3 beta (GSK-3β) 9-ING-41. Friday, May 17, 2019 With the Shire deal done, Takeda is looking to lighten the load a little from its central R&D base. To that end, it has launched a new biotech alongside Frazier Healthcare to take its late-stage gastrointestinal drug to the finish line. Thursday, May 16, 2019 Scientists from the University of Wisconsin-Madison and the University of Texas at Austin have turned to the jawless sea lamprey for inspiration in developing a new way to bypass the blood-brain barrier and ferry drugs directly to previously difficult-to-access diseased sites. Thursday, May 16, 2019 In this week's EuroBiotech Report, Bayer pumps $150 million into cell therapies, Merck KGaA retools F-star pact and Philogen raises $70 million. Friday, May 17, 2019 Takeda expects revenue to come in flat or slightly decline in a first glimpse at the combined business. Indian generics makers and their executives are named in a U.S. price-fixing suit. Daiichi's quizartinib got a thumbs-down from an FDA panel. And more. Friday, May 17, 2019 AstraZeneca hires R&D executive to lead breast cancer research and its $7 billion Daiichi drug pact; Teva stars in price-fixing scheme, but 19 others "willingly" joined, attorneys general claim; and EUSA Pharma nabs new executives, including Abeona's recently ousted CEO. Those moves plus more hirings, firings and retirings throughout the industry. | This week's sponsor is ExL Events. | | | |
Resources Sponsored by: Catalent Download the executive summary to learn key considerations for a successful technology transfer for manufacturing drug products, including a case study on overcoming challenges in a process transfer for a sterile diluent. Sponsored by: Patheon, part of Thermo Fisher Scientific Choosing the Best Sterile Dosage Form for Your Phase I Clinical Supply Needs. Sponsored by: Patheon, part of Thermo Fisher Scientific Designed with speed & flexibility,Quick to Clinic™ for Oral Solid Dose helps deliver products to Phase I Clinic in as little as 14 weeks. Sponsored by: AlphaSense What is agile competitive intelligence, and how can help healthcare researchers stay ahead of the curve? Sponsored by: JPEO-CBRND – Medical Countermeasure Systems MCS is currently seeking broad-based industry/academia collaboration on research and prototype work in technical areas related to developing medical countermeasures for the Joint Warfighter. Sponsored by: Outer Edge Technology Learn how the cloud can support the performance and security requirements for validated, mission-critical applications historically designed and implemented exclusively via on-premises deployment. Presented by: Total Brain Total Brain Announces Personalized Test for Treatment Prediction in Depression with 80% Accuracy. Sponsored by: Veradigm Prescription price transparency technology is here – but is it making a difference? Find out HERE. Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. 2019 BIO International Convention June 3-6, 2019 | Philadelphia, PA FierceBiotech Executive Breakfast at BIO 2019 – Getting Real: The Changing Tide on Real-World Evidence in Drug Development June 5, 2019 | Philadelphia, PA World Pharma Week June 17-20, 2019 | Seaport World Trade Center | Boston, MA Medical Sensors Design Conference June 25, 2019 | McEnery Convention Center | San Jose, CA Sensors Expo & Conference June 25-27, 2019 | McEnery Convention Center | San Jose, CA Drug Development Boot Camp® 2019 November 20-21, 2019 | Boston, MA | Register and start preparing Today! | 